Valuation: Novavax, Inc.

Market Cap 1.55B 1.36B 1.25B 1.17B 2.2B 146B 2.24B 15.01B 5.83B 72.27B 5.82B 5.69B 252B P/E 2026 *
-19.9x
P/E 2027 * -37x
Enterprise Value 1.77B 1.55B 1.43B 1.33B 2.51B 167B 2.56B 17.14B 6.65B 82.49B 6.64B 6.49B 287B EV / Sales 2026 *
4.31x
EV / Sales 2027 * 7.17x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day+0.64%
1 week+4.67%
1 month-14.13%
3 months+15.72%
6 months+40.18%
Current year+40.18%
1 week 8.26
Extreme 8.265
9.77
1 month 8.26
Extreme 8.265
10.58
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Date Insider Type Main position Quantity % Market Cap.
06-20Fiscal year

Director

37,760 0.0230%
06-20Fiscal year

Director

37,760 0.0230%
06-20Fiscal year

Director

37,760 0.0230%
Change 5-day change 1-year change 3-year change Capi.($)
+0.64%+4.67%+49.52%+26.78% 1.54B
+1.15%+5.94%-3.40%+2.32% 46.62B
-2.77%+10.48%+409.05%+600.11% 40.95B
-0.03%+12.81%+22.61%-14.04% 32.26B
-1.73%+3.20%+17.72%+59.83% 32.24B
-3.29%+7.98%+14.01%+29.96% 25.53B
+1.15%+11.79% - - 16.38B
-0.96%+11.85%+68.73%+120.51% 15.27B
+0.56%+5.09%+13.43%+17.88% 13.61B
-1.74%+4.34%+100.68%+93.25% 13.34B
Average -0.70%+7.24%+76.93%+104.07% 23.77B
Weighted average by Cap. -0.89%+7.69%+94.43%+136.85%

Financials

2026 *2027 *
Net sales 410M 359M 331M 309M 582M 38.76B 593M 3.97B 1.54B 19.13B 1.54B 1.51B 66.64B 258M 226M 209M 195M 367M 24.44B 374M 2.51B 973M 12.06B 971M 949M 42.01B
Net income -79.31M -69.42M -64.08M -59.77M -113M -7.5B -115M -769M -298M -3.7B -298M -291M -12.89B -43.22M -37.83M -34.92M -32.58M -61.38M -4.09B -62.48M -419M -163M -2.02B -162M -159M -7.03B
Net Debt 219M 192M 177M 165M 311M 20.71B 317M 2.12B 824M 10.22B 823M 804M 35.6B 303M 265M 245M 229M 431M 28.67B 438M 2.94B 1.14B 14.15B 1.14B 1.11B 49.29B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
30/06/26 $9.420 +0.64% 3,971,334
29/06/26 $9.360 +5.41% 4,039,729
26/06/26 $8.880 +3.74% 8,409,598
25/06/26 $8.560 -3.82% 4,370,755
24/06/26 $8.900 -1.11% 3,507,759
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
9.420USD
Average target price
14.11USD
Spread / Average Target
+49.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock